We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Oxford Biodynamics Plc | OBD | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 7.85 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 7.85 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 13/3/2024 19:57 by hatfullofsky 1.25m is just the primary bid raise they are raising another 9m from existing and new investors |
Posted at 13/3/2024 19:51 by jaf111 Good that HL on the ball….i wonder what you could have done though if you weren’t an existing shareholder?The Primary Bid blurb does state the fund raise is for both existing and new investor…..i do wonder how possible this would be for new investors in view of the tight timescale? |
Posted at 13/3/2024 17:18 by jaf111 Doe anyone know how to participate in the fund raise with Interactive Investors….Pri |
Posted at 11/1/2024 09:14 by hsdeo1 Notice of Results and Investor Webinar21 December 2023 - Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests based on the EpiSwitch(R) 3D genomics platform expects to announce its results for the year ended 30 September 2023 on Wednesday 17 January 2024. |
Posted at 05/1/2024 16:31 by waldron Notice of Results and Investor Webinar21 December 2023 - Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests based on the EpiSwitch(R) 3D genomics platform expects to announce its results for the year ended 30 September 2023 on Wednesday 17 January 2024. Following release of the results, the Company's management team will conduct a live presentation via the Yellowstone Advisory webinar platform to investors, at 3pm GMT on Wednesday 17 January 2024. THINGS SHOULD BECOME CLEARER AS TO OUTLOOK AD RESULTS APPROACHED CHUCKLE AND CHEERS |
Posted at 21/12/2023 11:06 by yellowstoneadvisory Oxford Biodynamics will release FY results for the year to 30 September 2023 on 17 January 2024.There will be a presentation for investors at 3pm that day and you can register for the event here. |
Posted at 19/12/2023 17:51 by rar100 I can't really understand the lack of news from the Co. I presume they are busy with a hell of a lot and could have a lot to write about (with investors in mind).The lack of news makes me twitchy, it's putting me off buying a few more. |
Posted at 15/12/2023 08:52 by intoodeep That's why I hardly bother posting on ADVFN BBs these days, unfortunately the owners of ADVFN are more interested in generating clicks rather than genuine discussions from genuine investors. |
Posted at 08/12/2023 10:10 by bigruss1 Oxford, UK - 2 AUGUST 2023 - Oxford BioDynamics PLC (AIM: OBD, "OBD", the "Company" and, together with its subsidiaries, the "Group"), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform, is pleased to announce that it has successfully raised gross proceeds of £5.6m pursuant to a placing, conducted via an accelerated bookbuild process (the "Placing") and through direct subscriptions (the "Subscription").Conditionally, in aggregate, 48,120,790 new ordinary shares of 1p ("Ordinary Shares") each in the Company will therefore be issued pursuant to the Placing (the "Placing Shares") at an issue price of 11p per new Ordinary Share ("Issue Price"). The Placing comprised both a General Placing and a VCT/EIS Placing. Subscribers have conditionally subscribed for, in aggregate, 2,528,634 new Ordinary Shares (the "Subscription Shares") at the Issue Price. In addition, retail investors are able to participate via the PrimaryBid platform (the "PrimaryBid Offer", and together with the Placing and the Subscription, the "Fundraising"). The PrimaryBid Offer remains open. Further details on the results of the PrimaryBid Offer will be announced separately. The Placing Shares and Subscription Shares represent approximately 25.7 per cent. of the Company's issued ordinary share capital as enlarged by the Placing and Subscription. Shore Capital and Baden Hill acted as joint brokers and bookrunners in connection with the Placing. Its clear to me there is still alot of share to flip and the downward trend will continue unlucky really for those spiked here ..Big sell off under way |
Posted at 27/10/2023 11:16 by smithie6 Kizjak"JUN 23 Tests 97" After 7-8 months from use/dale of first tests. Data can be looked at in many ways. CiRT test, I know very little about it. Call me a cynic but 97 tests when the world has ~8 billion people. Doesn't sound like the world was banging on the door desperate to use the test. 97 !! ===== Sure, shares move in advance of success/failure & investors will be thinking about possible sales in future years. But one perhaps needs some medical knowledge to get an opinion on that & to take the time to read the tech data about this CiRT test. Many investors are not willing/able to do that. ===== I've put money today in to Nat West. p/e of 4 More attractive risk/reward imo. And nett tang. assets per share higher than the share price. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
